¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ü"¿¡ ´ëÇÑ ´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • somatic crossing over
    ü¼¼Æ÷ ±³Â÷(ô÷á¬øàÎßó©)
  • somatic mutation
    ü¼¼Æ÷ º¯ÀÌ(ô÷á¬øàܨì¶)
  • somatic mutation theory
    ü¼¼Æ÷ º¯ÀÌÀÌ·Ð(ô÷á¬øàܨì¶×âÖå)
  • somatic cell genetic engineering
    ü¼¼Æ÷ À¯Àü°øÇÐ(ô÷á¬øàë¶îîÍïùÊ)
  • somatic theory
    ü¼¼Æ÷ ÀÌ·Ð(ô÷á¬øà×âÖå)
  • somatic recombination theory
    ü¼¼Æ÷ ÀçÁ¶ÇÕ ÀÌ·Ð(ô÷á¬øàî¢ðÚùê×âÖå)
  • somatic cell
    ü¼¼Æ÷(ô÷á¬øà)
  • somatic cell hybrid
    ü¼¼Æ÷(ô÷á¬øà) Æ¢±â
  • explant
    ü¿ÜÀÌ½Ä Á¶Á÷ (ô÷èâì¹ãÕðÚòÄ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absolute configuration
    Àý´ëÀÔüÇü»ó±¸Á¶ (ï¾Óßí¡ô÷û¡ßÀϰðã)
  • absorber
    Èí¼öü (ýåâ¥ô÷)
  • acceptor control
    ¼ö¿ëü Á¦¾î (â¥é»ô÷ ð¤åÙ)
  • acceptor-control ratio
    ¼ö¿ëü Á¦¾îÀ² (â¥é»ô÷ ð¤åÙëÒ)
  • accumulator organism
    ´©Àû°³Ã¼ (ÒéîÝËÁô÷)
  • acetone body
    ¾Æ¼¼ÅæÃ¼(ô÷)
  • acquired antibody
    "ȹµæÇ×ü (üòÔðù÷ô÷), ÈÄõ¼ºÇ×ü (ý­ô¸àõù÷ô÷)"
  • actin-myosin comolex
    ¾Çƾ¸¶ÀÌ¿À½Å º¹ÇÕü (ÜÜùêô÷)
  • acyl enzyme intermediates
    ¾Æ½ÇÈ¿¼Ò Áß°£Ã¼(ñéÊàô÷)
  • addition polymer
    ºÎ°¡ÁßÇÕü(ݾʥñìùêô÷)
  • adenohypophsis
    ¼±³úÇϼöü(àÍÒàù»á÷ô÷)
  • adrenergic receptor
    ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
  • aerial mycelium
    È£±â¼º ±Õ»çü(û¿Ñ¨àõжÞêô÷)
  • agglutinating antibody
    ÀÀÁýÇ×ü(ëêó¢ù÷ô÷)
  • aggregate
    ÀÀÁýü(ëêó¢ô÷)
ÅëÇÕ°Ë»ö ¿Ï·á